# Glaukos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glaukos

- Industry: Medical Devices & Equipment
- Headquarters: Laguna Hills, US
- Website: www.glaukos.com
- Total disclosed funding: $145M
- Latest round: Series F (Jan 22, 2013)
- Investors on record: 9

## About

Glaukos Corporation is dedicated to developing and commercializing innovative therapies for ophthalmic diseases, particularly focusing on advanced glaucoma treatments and corneal health solutions, thereby addressing significant unmet needs in eye care.Glaukos Corporation is a specialized company that develops innovative therapies for ophthalmic diseases. Founded in 1998 and headquartered in Laguna Hills, California, US, Glaukos has undergone multiple funding rounds, with the most notable being an IPO in June 2015, raising USD 108 mn. The company is led by CEO Lutz Temme and has completed a total of 8 deals to date, focusing on expanding its product offerings and market reach.Glaukos Corporation specializes in the development and commercialization of innovative therapies for ophthalmic diseases, focusing on glaucoma, corneal health, and retinal conditions. Their core offerings include a portfolio of advanced glaucoma treatments such as the iStent® and iDose® TR, which aim to lower intraocular pressure in patients with open-angle glaucoma. Additionally, Glaukos provides cross-linking interventions, like the iLink system, designed to halt or slow the progression of keratoconus, preserving patients’ vision. These products serve a diverse client base, including ophthalmologists, healthcare providers, and patients across key geographical markets, including the United States, Canada, Australia, New Zealand, and several European countries such as Spain and France.In 2024, Glaukos reported a revenue of USD 383.48 mn and an EBITDA of USD -81.73 mn. The company generates revenue primarily through the sale of its medical devices and therapies directly to healthcare providers, hospitals, and clinics, with transactions occurring in a B2B model. Their partnerships with distributors and wholesalers enhance product accessibility, and ongoing reinvestment in research and development aims to expand their offerings and enhance existing therapies.Glaukos plans to leverage its recent IPO funding of USD 108 mn, raised in June 2015, to support the development and launch of new products aimed at enhancing patient care in ophthalmology. The company is targeting expansion into new markets, particularly in Europe and Asia, with a strategic goal to enter these regions by the end of 2025. This growth strategy aligns with Glaukos' commitment to addressing the needs of ophthalmic disease management and improving patient outcomes globally.

## Funding rounds

- Series F, Jan 22, 2013, $30M — Domain Associates, Frazier Healthcare Partners, InterWest Partners, Meritech Capital Partners, OrbiMed Advisors, Versant Ventures, Montreux Equity Partners, Gund Investment Corporation
- Series E, Jan 25, 2011, $30M — Domain Associates, Frazier Healthcare Partners, InterWest Partners, OrbiMed Advisors, Versant Ventures, Montreux Equity Partners
- Series D, Aug 14, 2008, $35M — Domain Associates, Frazier Healthcare Partners, InterWest Partners, OrbiMed Advisors, Versant Ventures, Montreux Equity Partners, Fjord Ventures
- Series C, Jan 11, 2007, $40M — Domain Associates, Frazier Healthcare Partners, InterWest Partners, Versant Ventures, Montreux Equity Partners
- Series A, Sep 1, 2002, $10M — Domain Associates, Frazier Healthcare Partners, Versant Ventures

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A, Series C, Series D, Series E, Series F
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series C, Series D, Series E, Series F
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series C, Series D, Series E, Series F
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series C, Series D, Series E, Series F
- Montreux Equity Partners (https://capitalatlas.ai/funds/montreux-equity-partners) — Series C, Series D, Series E, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D, Series E, Series F
- Fjord Ventures (https://capitalatlas.ai/funds/fjord-ventures) — Series D
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series F
- Gund Investment Corporation — Series F